Primary |
Atrial Fibrillation |
40.2% |
Ventricular Tachycardia |
12.6% |
Arrhythmia |
7.7% |
Product Used For Unknown Indication |
7.6% |
Drug Use For Unknown Indication |
5.0% |
Hypertension |
4.1% |
Atrial Flutter |
2.9% |
Cardiac Failure |
2.7% |
Supraventricular Tachycardia |
2.1% |
Ventricular Fibrillation |
1.9% |
Ventricular Arrhythmia |
1.9% |
Prophylaxis |
1.6% |
Type 2 Diabetes Mellitus |
1.4% |
Tachyarrhythmia |
1.4% |
Cardiac Disorder |
1.3% |
Cardiac Failure Congestive |
1.3% |
Insomnia |
1.2% |
Gout |
1.1% |
Tachycardia |
1.0% |
Hyperlipidaemia |
1.0% |
|
Pulmonary Fibrosis |
8.9% |
Ventricular Tachycardia |
8.2% |
Pulmonary Toxicity |
8.0% |
Hyperthyroidism |
7.7% |
Drug Interaction |
7.0% |
Hypothyroidism |
6.7% |
Weight Decreased |
6.0% |
Torsade De Pointes |
5.4% |
Toxicity To Various Agents |
5.4% |
Tremor |
5.1% |
Lung Disorder |
4.8% |
Pneumonia |
3.6% |
Rhabdomyolysis |
3.1% |
Dyspnoea |
2.9% |
Pneumonitis |
2.9% |
Respiratory Failure |
2.9% |
Ventricular Fibrillation |
2.9% |
Vomiting |
2.9% |
Interstitial Lung Disease |
2.8% |
Drug Ineffective |
2.6% |
|
Secondary |
Atrial Fibrillation |
22.7% |
Drug Use For Unknown Indication |
16.1% |
Product Used For Unknown Indication |
14.5% |
Ventricular Tachycardia |
11.8% |
Hypertension |
6.4% |
Cardiac Failure |
4.2% |
Arrhythmia |
3.2% |
Cardiac Disorder |
3.0% |
Prophylaxis |
2.1% |
Cardiac Failure Congestive |
2.1% |
Thrombosis Prophylaxis |
1.9% |
Supraventricular Tachycardia |
1.8% |
Atrial Flutter |
1.7% |
Insomnia |
1.5% |
Ill-defined Disorder |
1.2% |
Pain |
1.2% |
Cardiac Failure Chronic |
1.2% |
Aortic Valve Replacement |
1.1% |
Pneumonia |
1.1% |
Ventricular Fibrillation |
1.1% |
|
Ventricular Tachycardia |
16.6% |
Blood Bilirubin Increased |
12.5% |
Torsade De Pointes |
6.5% |
Syncope |
6.1% |
Hepatic Steatosis |
5.4% |
Drug Ineffective |
4.7% |
Interstitial Lung Disease |
4.7% |
Renal Failure Acute |
4.7% |
Rhabdomyolysis |
4.7% |
Atrial Fibrillation |
4.3% |
Drug Interaction |
4.0% |
Pneumonia |
3.2% |
Vomiting |
3.2% |
Weight Decreased |
3.2% |
Renal Failure |
2.9% |
International Normalised Ratio Increased |
2.7% |
Paraesthesia |
2.7% |
Ventricular Fibrillation |
2.7% |
Hyperthyroidism |
2.5% |
Hypotension |
2.5% |
|
Concomitant |
Product Used For Unknown Indication |
31.2% |
Drug Use For Unknown Indication |
26.6% |
Atrial Fibrillation |
8.6% |
Hypertension |
6.9% |
Cardiac Disorder |
2.8% |
Coronary Artery Bypass |
2.5% |
Nuclear Magnetic Resonance Imaging |
2.3% |
Cardiac Failure |
2.1% |
Prophylaxis |
2.0% |
Multiple Myeloma |
1.8% |
Pain |
1.7% |
Osteoporosis |
1.6% |
Arrhythmia |
1.6% |
Diabetes Mellitus |
1.5% |
Chronic Obstructive Pulmonary Disease |
1.3% |
Blood Cholesterol Increased |
1.2% |
Rheumatoid Arthritis |
1.2% |
Cardiac Failure Congestive |
1.0% |
Depression |
1.0% |
Angiogram |
1.0% |
|
Vomiting |
10.0% |
Weight Decreased |
7.3% |
Renal Failure Acute |
7.2% |
Death |
6.9% |
Pain |
6.4% |
Ventricular Tachycardia |
6.1% |
Renal Failure |
5.7% |
Injury |
5.3% |
Unevaluable Event |
4.9% |
Pneumonia |
4.6% |
Sepsis |
4.2% |
Weight Increased |
4.2% |
Atrial Fibrillation |
4.1% |
Anxiety |
3.8% |
Fear |
3.6% |
International Normalised Ratio Increased |
3.2% |
Syncope |
3.2% |
Thrombocytopenia |
3.2% |
Myocardial Infarction |
3.1% |
Anhedonia |
3.0% |
|
Interacting |
Drug Use For Unknown Indication |
17.2% |
Atrial Fibrillation |
15.0% |
Product Used For Unknown Indication |
10.9% |
Supraventricular Tachycardia |
7.0% |
Ventricular Tachycardia |
5.9% |
Overdose |
5.3% |
Pneumonia |
4.9% |
Myocardial Ischaemia |
4.7% |
Arrhythmia |
4.0% |
Ill-defined Disorder |
3.6% |
Lower Respiratory Tract Infection |
3.0% |
Atrial Flutter |
2.6% |
Torsade De Pointes |
2.6% |
Cardiac Failure |
2.2% |
Immunosuppression |
2.2% |
Sinus Arrhythmia |
2.1% |
Antiplatelet Therapy |
1.7% |
Hyperlipidaemia |
1.7% |
Renal Failure Chronic |
1.7% |
Anticoagulant Therapy |
1.5% |
|
Drug Interaction |
26.1% |
Supraventricular Tachycardia |
12.7% |
Ventricular Fibrillation |
9.6% |
Torsade De Pointes |
5.7% |
Electrocardiogram Qt Prolonged |
5.1% |
Cardiac Arrest |
4.5% |
Renal Failure |
4.5% |
Pneumonia |
3.2% |
Rhabdomyolysis |
3.2% |
Toxicity To Various Agents |
3.2% |
Fall |
2.5% |
Intentional Overdose |
2.5% |
International Normalised Ratio Increased |
2.5% |
Sinus Bradycardia |
2.5% |
Thrombocytopenia |
2.5% |
Cholelithiasis |
1.9% |
Hepatic Enzyme Increased |
1.9% |
Myopathy |
1.9% |
Myositis |
1.9% |
Neurotoxicity |
1.9% |
|